Clomifene Citrate

Clomifene, sold as its citrate salt clomifene citrate, is a nonsteroidal selective estrogen receptor modulator, a class of drugs that behave as estrogen blockers in some tissues and estrogen mimics in others ^[1]. The commercial product is not a single molecule but a mixture of two geometric isomers, enclomifene and zuclomifene, which have distinct profiles; enclomifene, the larger fraction, is the more antiestrogenic and pro-fertility component, while zuclomifene is more estrogen-like and clears from the body more slowly ^[1]. Taken orally, the drug is well absorbed and undergoes liver metabolism through the enzyme CYP2D6, with traces detectable for weeks after a course ends ^[1].

The compound was first synthesised in 1956 by a team led by Frank Palopoli at the William S. Merrell Chemical Company, and after clinical development it was approved in the United States in 1967 under the brand name Clomid ^[1]. Its arrival is widely regarded as a milestone that helped open the modern era of fertility treatment, and it has since been marketed under dozens of trade names worldwide, including Serophene ^[1][3].

The main licensed use of clomifene is ovulation induction: in women who ovulate infrequently or not at all, a course taken early in the menstrual cycle prompts the ovaries to mature and release an egg, and it is a common first-line option in polycystic ovary syndrome ^[1][3]. Beyond fertility, the drug is used off-label in men with secondary hypogonadism, where it can substantially raise serum testosterone by increasing pituitary output of luteinising hormone and follicle-stimulating hormone while, unlike testosterone therapy, tending to preserve sperm production and fertility ^[1][4][5]. It has also been tried for gynecomastia, although other SERMs are generally considered more effective for that purpose ^[1].

Clomifene is a prescription-only medicine in the United States, the United Kingdom and Australia, and it is included on the World Health Organization Model List of Essential Medicines ^[1][3]. Because it stimulates the ovaries, treatment carries a raised chance of twins and higher-order multiple pregnancy, so cycles are often monitored by ultrasound to gauge the ovarian response ^[1][3]. Reported adverse effects include reversible ovarian enlargement, hot flashes, pelvic discomfort and reversible visual disturbances such as blurring or light sensitivity, while ovarian hyperstimulation syndrome is an uncommon but more serious risk ^[1][3]. The drug is supplied as oral tablets of the citrate salt, is available as an inexpensive generic in most markets, and is prohibited in competitive sport by the World Anti-Doping Agency because of its hormone-modulating action ^[1].

Clomifene is prescription only; its use in men and for post-cycle therapy is off-label. Common effects come from its estrogen-like and anti-estrogen actions and include hot flashes, mood swings, headaches, and breast tenderness. Visual disturbances such as blurring or flashes are an important signal to stop and call a doctor. In fertility use the main risks are multiple pregnancy, since more than one egg can release, and ovarian hyperstimulation, so cycles are monitored. It should not be used in pregnancy, active liver disease, or with unexplained abnormal bleeding, and long continuous courses are avoided.

Clomiphene is a selective estrogen receptor modulator metabolized primarily by CYP2D6 and CYP3A4, making it susceptible to pharmacokinetic interactions with inhibitors of these enzymes ^[17]. A physiologically-based pharmacokinetic model confirmed that CYP2D6 polymorphisms and concomitant use of strong CYP inhibitors such as clarithromycin and paroxetine substantially increase clomiphene exposure and active metabolite levels ^[17]. This is a pharmacokinetic interaction where the inhibitor raises clomiphene and metabolite levels. The clinical significance of these interactions in terms of efficacy or adverse effects remains incompletely characterized in the literature.

Clomiphene interacts with multiple CYP enzyme systems. CYP2D6 poor metabolizers and patients using CYP2D6 or CYP3A4 inhibitors may experience elevated clomiphene exposure. Beyond these metabolic interactions, documented interactions with anticoagulants and other common medications have not been clearly established in published clinical studies.

Checking a whole stack? Run it through interactions + stacks.

Clomifene citrate was first synthesized in 1956 at the William S. Merrell Company, part of the triphenylethylene chemical series that also gave rise to the related selective estrogen receptor modulator tamoxifen. Its ability to induce ovulation was recognized soon after, with early clinical reports around 1961, and it received United States approval in 1967, entering the market under names such as Clomid and Serophene.

For decades it stood as the first-line oral agent for inducing ovulation in anovulatory women, including many with polycystic ovary syndrome, and it earned a place on the World Health Organization list of essential medicines. A pivotal refinement of its role came from the PPCOS II trial, in which the aromatase inhibitor letrozole produced higher live-birth rates than clomifene in women with PCOS. The drug was also adopted off-label in men to raise endogenous testosterone and to aid recovery after anabolic steroid use.

Clomifene enjoys a reputation built on more than half a century of clinical experience as an inexpensive, oral, and effective ovulation inducer. It is valued for its accessibility and its long track record, qualities that kept it the default fertility treatment for anovulatory women for generations. Its standing has been refined rather than diminished by newer evidence; letrozole is now often preferred for live birth in PCOS, yet clomifene retains a firm place in fertility therapy and has expanded into off-label use for male hypogonadism and post-cycle recovery. Honestly assessed, its mixed agonist-antagonist nature can act against conception through antiestrogenic effects on the endometrium and cervical mucus, and its slowly clearing zuclomifene isomer can accumulate across cycles. These nuances are well understood and readily managed by experienced prescribers.